If the recruitment kept up that pace we could have 80 patients dosed by this point.
That is definitely enough patients to know if CF33 is what we all hope for.
That’s when we find out how many expansion trials we are planning. But it’s possible recruitment slowed to find exactly the right patients that had cancers with unmet needs that would enable IMU to apply for more fast track designations.
The more of these we have the more valuable our company is to others.
IMU Price at posting:
3.3¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)